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Abstract
Background: Plasmodium vivax is the most geographically widespread human malaria parasite. Cohort studies in Papua
New Guinea have identified a rapid onset of immunity against vivax-malaria in children living in highly endemic areas.
Although numerous P. vivax merozoite antigens are targets of naturally acquired antibodies, the role of many of these
antibodies in protective immunity is yet unknown.
Methodology/Principal Findings: In a cohort of children aged 1–3 years, antibodies to different regions of Merozoite
Surface Protein 3a (PvMSP3a) and Merozoite Surface Protein 9 (PvMSP9) were measured and related to prospective risk of P.
vivax malaria during 16 months of active follow-up. Overall, there was a low prevalence of antibodies to PvMSP3a and
PvMSP9 proteins (9–65%). Antibodies to the PvMSP3a N-terminal, Block I and Block II regions increased significantly with
age while antibodies to the PvMSP3a Block I and PvMSP9 N-terminal regions were positively associated with concurrent P.
vivax infection. Independent of exposure (defined as the number of genetically distinct blood-stage infection acquired over
time (molFOB)) and age, antibodies specific to both PvMSP3a Block II (adjusted incidence ratio (aIRR) = 0.59, p = 0.011) and
PvMSP9 N-terminus (aIRR = 0.68, p = 0.035) were associated with protection against clinical P. vivax malaria. This protection
was most pronounced against high-density infections. For PvMSP3a Block II, the effect was stronger with higher levels of
antibodies.
Conclusions: These results indicate that PvMSP3a Block II and PvMSP9 N-terminus should be further investigated for their
potential as P. vivax vaccine antigens. Controlling for molFOB assures that the observed associations are not confounded by
individual differences in exposure.
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Introduction
Historically, most malaria vaccine research and development
has been focused on Plasmodium falciparum. However, the impor-
tance of developing a P. vivax specific or combination P. falciparum/
P. vivax vaccine is increasingly being recognised [1]. P. vivax is the
most geographically widespread malaria parasite with up to 2.5
billion people at risk and an estimated 80–300 million clinical
cases every year [2]. It is not the benign parasite it was long
assumed to be; while severe manifestations are less common [3],
there is a spectrum of severe disease associated with P. vivax
infection that in many ways resembles that seen with P. falciparum
[4]. Furthermore, case fatality rates associated with severe P. vivax
or mixed P. falciparum/P. vivax infections are comparable with P.
falciparum [3,5,6]. Unique aspects of the biology of this particular
species of Plasmodium make it a challenge to treat and eradicate
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with currently available strategies [7,8,9,10]. P. vivax forms
dormant stages in the liver (hypnozoites), which can result in
relapses following effective anti-malarial treatment of blood-
stage infection [8]. It is also able to produce gametocytes early
in infection which may appear in the peripheral circulation
before the development of clinical symptoms [9]. Therefore, an
infected, asymptomatic but untreated individual serves as a
‘reservoir’, maintaining successful transmission of the parasite.
An effective P. vivax vaccine is a desirable, additional tool for P.
vivax elimination.
Prioritisation of malaria vaccine candidates is informed by their
site and stage expression, apparent function in vitro and role in
protective immunity in malaria exposed populations. The
identification and subsequent development of candidates for a P.
vivax specific vaccine has been challenging due to a number of
practical factors including the lack of a reliable in vitro culture
system and limited data with respect to antigen diversity. Several
antigens expressed during the blood stage of P. vivax infection have
been identified as potential vaccine candidates including the Duffy
Binding Protein (PvDBP, one of the primary erythrocyte invasion
ligands), Merozoite Surface Protein 3 (PvMSP3) and Merozoite
Protein 9 (PvMSP9) [11–14]. Antibodies against the most studied
P. vivax vaccine candidate, the PvDBP, have been shown to inhibit
binding of the parasite to receptors on the red blood cell and have
been associated with protection [15]. PvDBP Region II (RII), the
critical region for binding, is however quite polymorphic and the
protection observed in this study had a degree of strain specificity
[15]. This suggests that a vaccine based on PvDBP RII should
either target conserved epitopes and be able to induce broadly
inhibitory antibodies as recently demonstrated in vitro [16] or it
may need to include multiple allelic types. Additionally, recent
observations that P. vivax can utilise a Duffy antigen-independent
invasion pathway and invade Duffy-negative red cells [17] suggests
that a vaccine based solely on the PvDBP will not be effective
against all P. vivax strains. Consequently, it is essential that
additional P. vivax antigens are also critically assessed for their
potential as vaccine candidates.
The P. vivax MSP3 multigene family is expressed during the
erythrocytic stage of the life-cycle, with the majority of the
proteins expressed in the schizont stage when merozoites are
being formed [13,14,18]. Members are structurally related to P.
falciparum MSP3, which has been shown to mediate antibody-
dependent cellular-mediated inhibition [19] and is a vaccine
candidate that showed some efficacy in human trials following
preliminary analyses [20]. PvMSP3 lacks a hydrophobic region
which indicates the presence of a transmembrane domain that
could link it to the merozoite surface, rather it is thought to
associate with other surface anchored proteins [13]. Its central
alanine-rich domain with heptad repeats is predicted to form
coiled-coil tertiary structures which mediate protein-protein
interactions.
One of the members of the PvMSP3 family, originally identified
as PvMSP3a, has been the focus of several specific bodies of
research. Expression of PvMSP3a has been detected in tropho-
zoites and schizonts and is displayed at the surface of merozoites
[18,21]. This protein is highly polymorphic and it has therefore
been used as a molecular marker in P. vivax epidemiological and
population studies [22,23,24,25]. However, the hydrophilic,
extreme N-terminal and the acidic C-terminal domains of the
protein are relatively conserved [26]. Polymorphisms are clustered
in specific domains, mainly confined to the N-terminal half of the
central alanine-rich coiled-coil domain (designated as Block I,
residues 104–396) while the C-terminal portion of this domain
(designated Block II, residues 434–687) displays less variability
[26]. Block I may be deleted in some isolates while retention of the
relatively highly conserved Block II appears to be necessary. Due
to the relative conservation of Block II of the alanine rich domain
and the acidic C-terminal region, across a range of geographically
distinct isolates, it has been suggested that vaccine-based research
should focus on these regions [26]. PvMSP3a specific antibodies
have been detected in naturally exposed individuals resident in a
malaria endemic area of the Brazilian Amazon [21,27,28] and a
number of linear B cell epitopes defined, located primarily in the 2
blocks of repeats [27].
PvMSP9 is also expressed during schizogony and is associated
with the surface of the merozoite [29,30]. The deduced protein
contains a hydrophobic signal sequence, highly conserved N-
terminal domain with a cluster of 4 cysteines and a C-terminal
region containing 2 species-specific blocks of repeated amino
acids, designated PvMSP9-RI and PvMSP9-RII [29]. Its
importance as a vaccine candidate has been highlighted by
the ability of a PvMSP9 monoclonal antibody to block the entry
of P. vivax into erythrocytes [30]. Studies examining the
immunogenicity of different regions of PvMSP9 have demon-
strated the presence of both antibody and T cell responses
specific for this protein in individuals resident in malaria
endemic areas [12,31,32].
Recent cohort studies in Papua New Guinea (PNG), where
both P. falciparum and P. vivax co-exist, have identified an age-
dependent onset of immunity to the different Plasmodium species.
The incidence of P. vivax attributable illness peaks in the second
year of life, compared to P. falciparum where it continues to
increase until the 4th year of life, suggesting that immunity
against P. vivax appears to be acquired at a younger age than
that seen with P. falciparum [33]. This immunity is associated
with an increased ability to control parasite densities so that they
remain below the threshold above which symptoms are
apparent. Despite these observations, little is known about
immune responses against P. vivax antigens in young children
and how these may contribute to the acquisition of protective
immunity. To address this, we examined associations between
antibodies to different regions of the blood-stage antigens
PvMSP3a and PvMSP9 and prospective risk of P. vivax malaria
in a cohort of children aged 1–3 years residing in a malaria
endemic region of PNG.
Author Summary
Plasmodium vivax is the most geographically widespread
human malaria parasite. In highly endemic areas such as
Papua New Guinea, a very rapid onset of immunity against
vivax-malaria is observed. Although it is known that
numerous P. vivax merozoite antigens are targets of
naturally acquired antibodies, the role of many of these
antibodies in protective immunity is yet unknown. In a
cohort of 183 children aged 1–3 years, we now show that
the presence of antibodies to Merozoite Surface Protein 3a
(PvMSP3a) and Merozoite Surface Protein 9 (PvMSP9) are
associated with a significant reduction in the burden P.
vivax malaria. Antibodies increased with age and in the
presence of concurrent P. vivax infections. After adjusting
for both age and individual differences in exposure, the
strongest reductions in risk were seen in children with
antibodies to PvMSP3a Block II (41% reduction, p = 0.001)
and PvMSP9 N-terminal region. (32% reduction, p = 0.035).
These results indicate that PvMSP3a Block II and PvMSP9
N-terminus should be further investigated for their
potential as P. vivax vaccine antigens.
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Materials and Methods
Study description
This study was conducted in a rural area near Maprik, East
Sepik Province, Papua New Guinea. A detailed description of the
study is given elsewhere [33]. Briefly, 264 study participants aged
1–3 years (median 1.70; range 0.9–3.1 years) were enrolled
between March and September 2006 and venous blood collected.
Of these, 190 were enrolled at the study start and 74 over the
subsequent 6 months. Antibody assays were performed using
samples from 183 of the 190 children enrolled at the study start; all
data presented for the current analysis relates to these 183 children
only. Following enrolment, children were clinically examined
every 2 weeks for signs and symptoms of malaria for a period of up
to 16 months (until July 2007). In addition, children were actively
checked every 8 weeks, with visits scheduled over 2 consecutive
days (with 2 samples collected 24 hours apart) to improve
detection of low-level infection. A passive case detection system
was maintained at the local health centres and aid post throughout
the entire study period. At each episode of febrile illness, a blood
sample was collected, a rapid diagnostic test (RDT) was performed
and haemoglobin measured using Hemacue (Angholm, Sweden).
Anti-malarial treatment with CoartemH (Novartis, Switzerland)
was administered to any individual with a positive RDT or if
haemoglobin levels were ,7.5 g/dl. In children with a negative
RDT, blood slides were read within 24 hours and microscopy
positive children were treated with Coartem.
For the current analysis, a symptomatic episode of P. vivax
malaria was defined as the presence of fever plus parasitemia
.500 parasites/ml [34]. Parasitemia (ie absence/presence of
parasite) was determined by a semi-quantitative post-PCR ligase
detection reaction-fluorescent microsphere assay (LDR-FMA) [35]
and light microscopy was used to determine parasite density. All
analyses were performed using parasitemia determined by LDR-
FMA unless otherwise indicated.
Written informed consent was obtained from all parents or
guardians prior to recruitment of each child. Scientific approval
and ethical clearance for the study was obtained from the Medical
Research and Advisory Committee (MRAC) of the Ministry of
Health in PNG and the Human Research Ethics Committee, the
Walter and Eliza Hall Institute.
Antigens
PvMSP3a recombinant proteins, representing the N-terminal
(nucleotides 73–309), Block I (nucleotides 316–1242), Block II
(nucleotides 1246–2058) and the C-terminal (nucleotides 2059–
2353) regions were used. They were initially amplified from P.
vivax (Belem strain), expressed as His-tag recombinant proteins and
purified as previously described [27].
PvMSP9 recombinant proteins, representing the N-terminal
region (aa 34–193) and the C-terminal region containing the
repeated Blocks I and II (aa 729–972), were used. They were
initially amplified from P. vivax (Belem strain), expressed as GST
fusion proteins and purified as previously described [12,31].
The proteins were assessed on SDS-PAGE gels and via western
immunoblots using standard conditions. A single batch of each
protein was used for this was well as earlier Brazilian studies
[12,31].
Antibody assays
Samples collected from the enrolment bleed (n= 183) were used
in an enzyme linked immunosorbent assay (ELISA). All available
samples were tested for IgG. ELISAs were performed using
established methods [36]. Ninety-six well plates (Nunc, Roskilde,
Denmark) were coated with MSP3a and MSP9 recombinant
proteins in PBS and incubated overnight at 4uC. For MSP9
proteins, GST alone was used as a control antigen. Skim milk-
PBS-0.05% Tween was used for blocking and for diluting plasma
and antibodies. Plasma was added in duplicate at previously
determined dilutions. For measurement of total IgG, horseradish
peroxidase-conjugated sheep anti-human IgG (Chemicon, Mel-
bourne, Australia) was used at a dilution of 1, 2:500. Finally, o-
phenylenediamine dihydrochloride substrate (Sigma, Castle Hill,
Australia) was added and the reaction stopped using 3M HCl with
optical density determined at 492 nm. All samples were tested in
duplicate. Standardization of the plates was achieved using
positive control plasma pools on each plate. Background
(determined from the wells with no plasma) was deducted from
the mean of each sample and a cut-off threshold for positivity
determined as the mean plus 3 standard deviations of negative
control plasma samples (Australian residents) included in each
assay. For MSP9 proteins, final OD values were determined by
subtracting the mean OD value to GST alone from the mean OD
value of the same plasma for the recombinant proteins.
Measuring Force of Blood-stage infection (molFOB)
The molFOB was used to define the number of new P. vivax
blood-stage clones acquired during the study follow-up period
[37]. For genotyping individual P. vivax clones, the highly
polymorphic molecular markers Merozoite Surface Protein 1 F3
fragment and the microsatellite MS16 were typed using capillary
electrophoresis for precise fragment sizing. Details of the
genotyping techniques have been described elsewhere [38].
Statistical analyses
Antibody levels were not normally distributed, so non-
parametric tests (Mann-Whitney U tests) were used for analyses
of antibody titres. Differences in the prevalence of antibodies with
age and infection status as well as associations between antibodies
to different proteins were assessed using Chi-square test with the
strength of the association between antibodies of different
specificities measured by the phi coefficient (rw). The association
of antibody prevalence and parasite density were assessed using
generalised estimating equation (GEE) models.
Children were followed up for a maximum of 8 periods during
the study, each spanning 8–9 weeks and consisting of 3 fortnightly
surveillance visits and each concluding with the collection of 2
blood samples 24 hours apart for active detection of malaria
infection. Incidence of clinical malaria in each 8–9 week follow-up
interval was estimated as previously described, with P. vivax clinical
episodes defined as febrile illness (axillary temperature $37.5uC or
history of fever in preceding 48 hrs) with a concurrent P. vivax
parasitemia .500 parasites/ml. A negative binomial GEE model
(based on XTNBREG procedure in STATA 12.0), an exchange-
able correlation structure and semi-robust variance estimator were
used for the analysis of incidence of P. vivax malaria. For each
follow-up interval, children were considered at risk from the first
day after the second or only blood sample for active follow-up was
taken. Therefore, cross-sectional bleeds were considered as part of
the preceding 8–9 week interval and clinical episodes detected
during those cross-sectional bleeds (2 samples taken 24 hours
apart) were included in that interval. Children were not considered
at risk for 2 weeks after treatment with CoartemH.
Three different models were used to assess the association of
antibodies with protection: i) ‘crude’: adjustment only for seasonal
(month, year) and spatial variation (village or residence) as well as
for individual differences in exposure: aIRR(exp); ii) age-adjusted:
additional adjustment for age of child (as a correlate of overall
Natural Immunity to P. vivax MSP3a and MSP9
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immune status): aIRR(exp+age), iii) multivariate age-adjusted:
multivariate analyses of all antibodies univariately associated with
protection: aIRR(multi), with the best model determined by
backward elimination using Wald’s Chi-square tests for individual
variables.
Individual differences in exposure were described by the
number of genetically distinct P. vivax clones a child acquired
during 2 month intervals, expressed as the number of new blood-
stage infections per unit of time. Samples from scheduled bleeds as
well as morbidity surveillance were used. The force of infection for
each child was therefore defined as the number of new blood-stage
clones acquired per year at risk (i.e. the molecular force of
infection molFOB [39]). In order to improve the fit, molFOB was
cube-root transformed [37].
Results
P. vivax prevalence in the cohort
A total of 183 children 0.9–3.1 years (47.5% $21 months,
56.8% male) were enrolled in late March 2006 and actively
followed for 16 months for the development of malaria
infection. At enrolment, the prevalence of P. vivax was 39.9%
and 49.2% by light microscopy (LM) and post-PCR LDR-FMA,
respectively. During follow-up, P. vivax prevalence ranged from
59.9–79.2% by post-PCR LDR-FMA and 47.3–59.9% by LM.
Children experienced an average of 2.47 (CI95 [2.15, 2.85]) P.
vivax episodes with any level of parasitemia and 1.49 (CI95 [1.24,
1.79]) episodes with P. vivax .500 parasites/ml per year at risk.
The patterns of P. vivax infection and disease in the immunology
sub-cohort are therefore comparable to those observed in the
entire cohort [33,38].
Presence of IgG antibodies and their association with age
and infection status
The frequency of IgG responses at enrolment to the different
antigens ranged from 8.7%–65% (Table 1). When comparing
different regions of PvMSP3a, significantly more children had IgG
antibodies to the C-terminal than to the N-terminal, Block I and
Block II proteins of PvMSP3a (65.0% vs. 36.1–38.3%, p,0.001).
The presence of antibodies to the different protein constructs
derived from PvMSP3a were highly associated with each other
(p,0.0001 for any pair) with the strongest association found
between antibodies to Block II and Block I (rw=0.67). Overall, 43
children (23.5%) had antibodies to all 4 PvMSP3a proteins while
51 (27.9%) had antibodies to none (Figure 1a).
Children $21 months were significantly more likely to have
antibodies to the PvMSP3a N-terminal protein (Odds ratio
(OR=2.06, CI95 [1.08, 3.95], p = 0.019), Block I (OR=2.53,
CI95 [1.30, 4.95], p = 0.003) and Block II (OR=2.27, CI95 [1.18,
4.37], p = 0.008) but not to the C-terminal protein (Figure 1b).
Antibodies to Block I (OR=2.06, CI95 [1.07, 4.00], p= 0.020)
were also significantly more common in children with concurrent
P. vivax infection (Figure 1c). There were no significant associations
with antibody levels and either age or infection status among
children that were antibody-positive for any of the PvMSP3a
proteins (p.0.26).
Eighty-four (45.9%) children had antibodies to the PvMSP9 N-
Terminal region, and 16 (8.7%) had antibodies to the MSP9
protein spanning RI-RII (Table 1). Children that were positive for
any of the PvMSP3a proteins were more likely to also be positive
for the PvMSP9 N-Terminus (OR=2.30–4.78, p,0.009). Anti-
bodies specific for the PvMSP9 N-Terminus were more common
in children with concurrent P. vivax infection (OR=2.38, CI95
[1.26, 4.51], p = 0.004). No other significant associations between
antibodies specific for PvMSP9 derived proteins and either age or
infection status were observed.
Association between presence of antibodies and
prospective risk of P. vivax malaria
When assessing associations between the presence of IgG
antibodies specific for the different PvMSP3a and PvMSP9
proteins and prospective risk of P. vivax clinical episodes (.500
parasites/ml, Table 2) during the 16 months of follow-up,
adjustments were made first for different measures of malaria
exposure as described in the materials and methods section,
designated aIRR(exp). This was followed by a further adjustment
for age, designated aIRR(exp+age).
After adjusting for malaria exposure, a significant decrease in
the risk of clinical P. vivax malaria was associated with the presence
of antibodies for PvMSP3a Block II (aIRR(exp) = 0.46, p,0.001),
PvMSP3a N-terminus (aIRR(exp) = 0.67, p = 0.048), and PvMSP9
N-Terminus (aIRR(exp) = 0.58, p = 0.004) (Table 2).
Following a further adjustment for age, a significantly decreased
risk remained for individuals who were antibody positive for
PvMSP3a Block II (aIRR(exp+age) = 0.53, p = 0.001) and PvMSP9
N-Terminus (aIRR(exp+age) = 0.60, p = 0.004) (Table 2). For
antibodies specific for both these proteins there was a tendency
for protection to increase with increasing levels of parasitaemia
(Figure 2). However, whereas the presence of antibodies for
PvMSP3a Block II was associated with protection against all
clinical episodes with a P. vivax parasitaemia $500/ml (p = 0.003–
0.057), antibodies against PvMSP9 N-Terminus were associated
only with significant protection against episodes with $2000/ml
(p = 0.001–0.002) but not those with densities ranging from 500–
1999/ml (p = 0.92).
To assess the effect of antibody levels on protection against risk
of P. vivax clinical episodes, children who were antibody positive
for PvMSP3a Block II or PvMSP9 N-Terminus were stratified
into 2 equal sized groups: those with high levels and those with low
levels of antibodies. High levels (OD.0.77) of PvMSP3a Block II
specific antibodies were significantly associated with protection
(aIRR=0.42, p= 0.001) whereas, this was not observed with lower
levels (IRR=0.68, p = 0.114). No such differences were observed
with antibodies to PvMSP9 N-Terminus.
In multivariate analyses, both antibodies to PvMSP3a Block II
(aIRR(multi) = 0.59, p= 0.011) and PvMSP9 N-Terminus (aIR-
R(multi) = 0.68, p = 0.035) remained significantly associated with a
reduced risk of P. vivax (Table 2). A significant interaction between
the presence of antibodies to PvMSP9 N-Terminus and concur-
rent P. vivax infection was observed (X2= 4.55, p= 0.033) with
PvMSP9 N-Terminus antibodies associated with protection only
in children without concurrent P. vivax infection (aIR-
R(multi) = 0.48, CI95[0.28, 0.80], p = 0.006), while in children with
concurrent infection PvMSP9 N-Terminus, antibodies did not add
any extra protection (aIRR(multi) = 1.03, CI95[0.62, 1.71], p= 0.9)
besides that associated with concurrent infection itself (aIR-
R(multi) = 0.59, CI95[0.41, 0.87], p= 0.007).
As multivariate analyses examining the relationship between the
presence of antibodies and risk of clinical P.vivax malaria showed a
protective effect with only PvMSP3a Block II and MSP9 N-
terminus, further analyses examining the effect of antibody levels
were restricted to these 2 proteins. Antibody positive children were
stratified into 2 equal sized groups and designated as high or low
responders. Children with high antibody levels to both PvMSP3a
Block II (high: aIRR=0.46, CI95[0.28, 0.77], low: aIRR=0.72,
CI95[0.45, 1.17]) and PvMSP9 N-Terminus (without concurrent
infection, high: aIRR=0.30, CI95[0.14, 0.62], low: IRR=0.76,
CI95[0.40, 1.45]), had a lower risk of clinical P. vivax malaria
Natural Immunity to P. vivax MSP3a and MSP9
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compared to children with low antibody levels but that difference
was only significant for PvMSP9 N-Terminus (p = 0.04) and not
PvMSP3a Block II (p = 0.15).
There were no significant associations observed with antibodies
to any of the P. vivax proteins and risk of P. falciparum clinical
episodes (p.0.16).
Discussion
Antigens on the surface of the merozoite have long been
considered as promising vaccine candidates based on their
accessibility to the immune system. Antibodies against P. vivax
merozoite surface proteins and their P. falciparum orthologues are
Figure 1. IgG positivity to different PvMSP3a and PvMSP9 proteins. (a) Cumulative IgG positivity for different PvMSP3a proteins. Data are
plotted as the percentage of 183 individuals who are antibody positive for 0–4 of the proteins tested. (b) Associations between age and IgG positivity
to PvMSP3a and PvMSP9 proteins. Children were divided into two age groups (,21 mths: n = 96, $21 mths: n = 87) to examine associations with
age. P values#0.05 were considered significant and are shown. (c) Associations between P. vivax infection status (post-PCR LDR-FMA positive: n = 90,
negative: n = 93) and IgG positivity to PvMSP3a and PvMSP9 proteins. As indicated, the presence of P. vivax was determined by a semi-quantitative
post-PCR ligase detection reaction-fluorescent microsphere assay (LDR-FMA). P values#0.05 were considered significant and are shown.
doi:10.1371/journal.pntd.0002498.g001
Table 1. Optical density values (OD) as a measurement of total IgG to different PvMSP3a and PvMSP9 proteins.
PvMSP3a PvMSP9
N-terminal C-terminal Block I Block II N-terminal RI-RII
Median OD (IQR) 0.26 [0.07,0.67] 0.33 [0.15,0.62] 0.28 [0.12,0.74] 0.27 [0.09,0.67] 0.39 [0.18,0.98] 0.05 [0.02,0.14]
OD value ranges minimum-maximum 0.01–2.25 0.03–1.63 0.01–1.74 0.02–1.60 0.03–2.35 0.00–2.00
OD positivity cut-offa 0.43 0.21 0.43 0.44 0.48 0.43
Frequency of respondersb (n) 38.3% (70) 65.0% (119) 36.1% (66) 38.3% (70) 45.9% (84) 8.7% (16)
aThe cut-off for positivity was determined as the mean+3 standard deviations of negative control plasma samples (Australian residents) included in each assay.
bResponders defined as individuals whose plasma OD value was above the cut-off for positivity for a given antigen.
doi:10.1371/journal.pntd.0002498.t001
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thought to function by directly inhibiting invasion of erythrocytes,
opsonising merozoites for uptake by phagocytes and through
antibody-dependent cell-mediated immune mechanisms
[19,30,40,41,42,43,44,45]. Although studies have established the
immunogenicity of a number of P. vivax merozoite antigens
using serum from malaria exposed individuals
[10,12,21,27,28,31,46,47,48], few have examined the contribu-
tion of antibodies to protective immune responses against P.
vivax infection in malaria exposed populations [15,27,31,49,50].
Our results demonstrate that IgG specific responses against
Table 2. Association between antibody positivity and protection against subsequent P. vivax malaria (density.500/ml).
Models used to assess the association of antibodies with protection
‘Crude’a Age-adjustedb Multivariatec
aIRR(exp) CI95 p -value aIRR(exp+age) CI95 p -value aIRR(multi) CI95 p -value
PvMSP3a N-term 0.67 [0.44,1.00] 0.048 0.79 [0.54,1.15] 0.222
C-term 0.77 [0.54,1.12] 0.172 0.82 [0.58,1.16] 0.267
Block I 0.72 [0.50,1.04] 0.077 0.75 [0.53,1.07] 0.116
Block II 0.46 [0.31,0.68] ,0.001 0.53 [0.36,0.77] 0.001 0.59 [0.40,0.89] 0.011
PvMSP9 N-term 0.58 [0.40,0.84] 0.004 0.60 [0.42,0.85] 0.004 0.68 [0.47,0.97] 0.035
RI-RII 0.81 [0.42,1.54] 0.515 0.97 [0.51,1.82] 0.915
aAdjustment for season (month, year), spatial variation (village or residence) and individual differences in exposure (as measured by molecular force of blood-stage
infection (molFOB).
bAdjustment for age of child, season (month, year), spatial variation (village or residence) and individual differences in exposure (as measured by molecular force of
blood-stage infection (molFOB).
cAdjustment as performed for age-adjusted b. Multivariate analyses of antibodies univariately associated with protection.
doi:10.1371/journal.pntd.0002498.t002
Figure 2. Association between antibodies to PvMSP3a(Block II) and PvMSP9(N-terminal) proteins and risk of P. vivax malaria. Data
are plotted as exposure and age adjusted incidence rate ratios (aIRR(exp)) 6 95% confidence intervals for febrile episodes with different levels of
concurrent P. vivax parasitaemia.
doi:10.1371/journal.pntd.0002498.g002
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defined regions of PvMSP3a and PvMSP9 are significantly
associated with protection from symptomatic P. vivax infection in
young children resident in a malaria endemic region of PNG.
Antibody responses against these proteins have been previously
examined in malaria-exposed populations [27,31] however,
these studies were limited in their ability to precisely define the
role of these antibodies. We employed a longitudinal study
design with active screening for re-infection and morbidity and
related antibody responses at baseline with prospective risk of
developing symptomatic P. vivax infection over the 16-month
follow-up period.
Overall, the prevalence of IgG specific responses to the different
PvMSP3a and PvMSP9 antigens was low. Patterns of responsive-
ness to the recombinant proteins were different to that observed in
previous studies [27,31]. This is likely to reflect differences in age
ranges, malaria transmission levels and potentially population
genetics. However, we cannot rule out that differences in the
reactivities of the non-exposed donors that were used to establish
the threshold for seropositivity in the different studies may have
contributed to disparity between studies. Although the age range
of this cohort was narrow, the prevalence of antibodies against all
PvMSP3a proteins and the PvMSP9 RI-RII domain increased
with age (and presumably exposure). This was only significant
however for antibodies against the N-terminal and the Block I and
II regions of PvMSP3a. Interestingly, there was no apparent effect
of age on the prevalence of antibodies against the PvMSP9 N-
terminus. As this region of PvMSP9 is known to be highly
conserved [29,30] this may reflect the presence and recognition of
conserved epitopes. Antibodies against all of the PvMSP3a and
PvMSP9 antigens were also more commonly found in individuals
with concurrent P. vivax infection, although this difference was only
significant for Block I PvMSP3a and the PvMSP9 N-terminus.
This effect of active parasite infection on antibody positivity
reflects the induction and/or boosting of existing antibody
responses.
After adjusting for age and exposure, associations with
protection from symptomatic P. vivax malaria were seen for
antibodies against the PvMSP3a Block II and the PvMSP9 N-
terminal domains. This association remained following multivar-
iate analyses. Additionally, antibodies against these proteins were
associated with stronger reduction in risk of high compared to low
infections. This density-dependent effect is in keeping with the
proposed mechanism of action of these antibodies (i.e., to prevent/
interfere with merozoite invasion of red blood cells and/or
opsonisation of merozoites). This is most evident for PvMSP3a
Block II, where higher levels of antibodies were associated with a
significantly stronger protection compared with lower levels.
Although PvMSP9 specific antibodies were more prevalent in
children with concurrent infections, these antibodies were only
associated with protection in children who did not have
concurrent P. vivax infections at the time of antibody measurement.
This indicates the existence of at least two separate types of
antibodies targeting the PvMSP9 N-terminal domain: one that is
easily boosted by infection and another that is longer lasting and
continues to be present after an infection is cleared. Only the latter
appear to be associated with protection against clinical P. vivax
malaria. Whether these differential antibody types indicate the
induction of different IgG subclass responses or target different
epitopes is yet unknown.
A recent study demonstrated that the majority of sequences
containing linear B cell epitopes within PvMSP3a are localised
within the Block I and II repeat regions, although a few epitopes
were detected in the more conserved N- and C-terminal flanking
regions [27]. While the central domain of PvMSP3a is highly
polymorphic, the C-terminal half containing the Block II repeat
region is relatively conserved with only 2 major regions of
polymorphism [26]. The PvMSP9 N-terminus is also known to
be highly conserved across Plasmodium species [29,30]. The
conservation of these antigens amongst P. vivax isolates
highlights their potential as vaccine candidates. Additionally, it
has recently been shown that anti-sera generated against
individual recombinant proteins representing the central
alanine-rich domain of different PvMSP3 family members
(including PvMSP3a), contain antibodies capable of recognising
the central domain of other PvMSP3 family members [18].
While this suggests that an immune response generated against a
single PvMSP3 protein may consist of a broad antibody
response against multiple antigenic targets, further studies are
required to determine whether the B cell epitopes recognised by
these cross-reactive antibodies are contained within the C-
terminal half of this domain. Studies to identify and characterise
B cell epitopes that are targets of protective antibodies would
inform the development and use of these molecules. Further-
more, investigating the functionality of antibodies against the
PvMSP9 N-terminus and PvMSP3a Block II would confirm the
utility and importance of these proteins as vaccine candidates.
Undertaking ex vivo invasion assays with affinity purified serum
containing antibodies specific for these proteins together with a
range of P.vivax isolates would also shed light on the strain-
transcending nature of the antibody response. In conclusion,
these findings have significant implications for the development
of a P. vivax specific vaccine. Controlling for molFOB ensures
that the observed associations of antibodies specific for the
PvMSP9 N-terminus and PvMSP3a Block II with protection
against P. vivax malaria in this study are not confounded by
individual differences in exposure. Our results support further
investigation of the PvMSP9 N-terminus and PvMSP3a Block II
as vaccine candidates.
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